186 related articles for article (PubMed ID: 37298104)
1. Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).
Celesia A; Franzò M; Di Liberto D; Lauricella M; Carlisi D; D'Anneo A; Notaro A; Allegra M; Giuliano M; Emanuele S
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298104
[TBL] [Abstract][Full Text] [Related]
2. The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis.
Celesia A; Notaro A; Franzò M; Lauricella M; D'Anneo A; Carlisi D; Giuliano M; Emanuele S
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009541
[TBL] [Abstract][Full Text] [Related]
3. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
4. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
Liu D; Liu X; Xing M
Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
[TBL] [Abstract][Full Text] [Related]
5. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
6. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Lai F; Guo ST; Jin L; Jiang CC; Wang CY; Croft A; Chi MN; Tseng HY; Farrelly M; Atmadibrata B; Norman J; Liu T; Hersey P; Zhang XD
Cell Death Dis; 2013 Jun; 4(6):e655. PubMed ID: 23744355
[TBL] [Abstract][Full Text] [Related]
8. Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
Jang GH; Kim NY; Lee M
Mol Cell Biochem; 2015 Aug; 406(1-2):53-62. PubMed ID: 25912549
[TBL] [Abstract][Full Text] [Related]
9. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
Salas Fragomeni RA; Chung HW; Landesman Y; Senapedis W; Saint-Martin JR; Tsao H; Flaherty KT; Shacham S; Kauffman M; Cusack JC
Mol Cancer Ther; 2013 Jul; 12(7):1171-9. PubMed ID: 23615632
[TBL] [Abstract][Full Text] [Related]
10. Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance.
Kim N; Shin I; Lee J; Jeon E; Kim Y; Ryu S; Ju E; Cho W; Sim T
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917428
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.
Patton EE; Widlund HR; Kutok JL; Kopani KR; Amatruda JF; Murphey RD; Berghmans S; Mayhall EA; Traver D; Fletcher CD; Aster JC; Granter SR; Look AT; Lee C; Fisher DE; Zon LI
Curr Biol; 2005 Feb; 15(3):249-54. PubMed ID: 15694309
[TBL] [Abstract][Full Text] [Related]
12. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
[TBL] [Abstract][Full Text] [Related]
14. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
Wilking MJ; Singh C; Nihal M; Zhong W; Ahmad N
Arch Biochem Biophys; 2014 Dec; 563():94-100. PubMed ID: 24751483
[TBL] [Abstract][Full Text] [Related]
15. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
[TBL] [Abstract][Full Text] [Related]
16. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
Madorsky Rowdo FP; Barón A; Gallagher SJ; Hersey P; Emran AA; Von Euw EM; Barrio MM; Mordoh J
Int J Oncol; 2020 Jun; 56(6):1429-1441. PubMed ID: 32236593
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
20. MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function.
Pascucci FA; Ladelfa MF; Toledo MF; Escalada M; Suberbordes M; Monte M
Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118918. PubMed ID: 33279609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
